OBJECTIVE: The aim of this study was to assess the health-related quality of life of @entity1 with @entity263 in advanced phases to obtain additional information on the @entity1 ' health. The growing interest in understanding the @entity1 's perspective and the scarcity of prospective studies of this population motivated this research study. MATERIAL AND METHODS: We present an observational study performed on 131 urology consultations, with a sample of 601 @entity1 with locally advanced or @entity263 , assessed during 2 visits: baseline and at 12 months. We collected demographic, clinical, quality-of-life (PROSQoLI and EuroQoL-5D-5L questionnaires) and @entity308 (HADS questionnaire) endpoints. RESULTS: The mean age (SD) was 73.8 (8.2) years, and 87.2% of the @entity1 were retired or pensioners. Some 58.7% of the @entity1 presented locally advanced @entity263 . Urinary symptoms were the most common, decreasing significantly after one year (P<.05). Urinary problems and fatigue were the most affected measures, and @entity158 /discomfort was the dimension present in most @entity1 (65.3%). According to the linear regression model, @entity1395 and @entity158 were 2 of the factors most closely related to a poorer quality of life. The presence of @entity308 was low. Finally, the health condition as assessed by the clinician was more positive than when assessed by the @entity1 . CONCLUSIONS: This study broadens the scarce information on the quality of life of the population with advanced @entity263 , information of use for the clinical management of these @entity1 .

Impact of locally advanced or XXXX on the quality of life.

@entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'patient'] @entity308 :: ('MESH:D003866', 'Disease') :: ['anxiety/depression'] @entity263 :: ('MESH:D011471', 'Disease') :: ['metastatic prostate cancer', 'prostate cancer'] @entity1395 :: ('MESH:D001247', 'Disease') :: ['asthenia'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain']
@entity263 :: (MESH:D011471,Disease) :: ['metastatic prostate cancer']
